{"id":"ad26-zebov-mva-bn-filo-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The Ad26.ZEBOV vaccine primes the immune system with an adenovirus-vectored Ebola glycoprotein, followed by an MVA-vectored boost to enhance and broaden the immune response. This heterologous prime-boost strategy leverages two different viral vectors to maximize T-cell and antibody responses against Ebola virus, providing durable protection against infection.","oneSentence":"A two-dose heterologous prime-boost vaccine regimen that uses recombinant adenovirus 26 (Ad26) and modified vaccinia Ankara (MVA) vectors expressing Ebola virus glycoprotein to elicit cellular and humoral immune responses against Ebola virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:32.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Ebola virus disease (Zaire ebolavirus)"}]},"trialDetails":[{"nctId":"NCT02891980","phase":"PHASE1","title":"A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-24","conditions":"Ebola Disease, Marburg Disease","enrollment":65},{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329},{"nctId":"NCT04228783","phase":"PHASE3","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-02-18","conditions":"Ebola","enrollment":974},{"nctId":"NCT03929757","phase":"PHASE2","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-08-19","conditions":"Ebola Virus Disease","enrollment":108},{"nctId":"NCT02543567","phase":"PHASE3","title":"A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-21","conditions":"Healthy","enrollment":525},{"nctId":"NCT05284097","phase":"PHASE2","title":"Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-09-19","conditions":"Virus Diseases, Hemorrhagic Fever, Ebola, Infections","enrollment":133},{"nctId":"NCT02598388","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-12-10","conditions":"Hemorrhagic Fever, Ebola","enrollment":578},{"nctId":"NCT04556526","phase":"PHASE3","title":"A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-10-05","conditions":"Healthy","enrollment":4031},{"nctId":"NCT02876328","phase":"PHASE2","title":"Partnership for Research on Ebola VACcinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-27","conditions":"Ebola Virus Disease","enrollment":4789},{"nctId":"NCT02661464","phase":"PHASE3","title":"Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-05-31","conditions":"Hemorrhagic Fever, Ebola","enrollment":677},{"nctId":"NCT04711356","phase":"PHASE2","title":"Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-07-08","conditions":"Ebola Virus Disease","enrollment":50},{"nctId":"NCT05064956","phase":"PHASE2","title":"Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-06","conditions":"Ebola Virus Disease, Ebola, Hiv","enrollment":26},{"nctId":"NCT03820739","phase":"","title":"EBOVAC-Salone Extension","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-07-22","conditions":"Ebola Virus Disease","enrollment":653},{"nctId":"NCT04186000","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2019-12-18","conditions":"Ebola Virus Disease","enrollment":699},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075},{"nctId":"NCT04152486","phase":"PHASE3","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-11-14","conditions":"Ebola Virus Disease","enrollment":20426},{"nctId":"NCT04028349","phase":"PHASE2","title":"ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2019-08-01","conditions":"Ebola Virus Disease","enrollment":800},{"nctId":"NCT02416453","phase":"PHASE2","title":"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-06-15","conditions":"Ebola Viral Disease","enrollment":423},{"nctId":"NCT03140774","phase":"","title":"Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-05-17","conditions":"Ebola Virus Disease","enrollment":126},{"nctId":"NCT02860650","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT02325050","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-01-08","conditions":"Healthy","enrollment":164},{"nctId":"NCT02313077","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2014-12-17","conditions":"Healthy","enrollment":87},{"nctId":"NCT02376426","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-03","conditions":"Healthy","enrollment":72},{"nctId":"NCT02376400","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-04","conditions":"Healthy","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ad26.ZEBOV, MVA-BN-Filo vaccine","genericName":"Ad26.ZEBOV, MVA-BN-Filo vaccine","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Biologic","firstApprovalDate":"","aiSummary":"A two-dose heterologous prime-boost vaccine regimen that uses recombinant adenovirus 26 (Ad26) and modified vaccinia Ankara (MVA) vectors expressing Ebola virus glycoprotein to elicit cellular and humoral immune responses against Ebola virus. Used for Prevention of Ebola virus disease (Zaire ebolavirus).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}